Nagel, Holger

[["dc.bibliographiccitation.firstpage","35"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","CANCER GENETICS AND CYTOGENETICS"],["dc.bibliographiccitation.lastpage","47"],["dc.bibliographiccitation.volume","176"],["dc.contributor.author","Schulten, Hans Juergen"],["dc.contributor.author","Perske, Christina"],["dc.contributor.author","Thelen, Paul"],["dc.contributor.author","Polten, Andreas"],["dc.contributor.author","Borst, Christoph"],["dc.contributor.author","Gunawan, Bastian"],["dc.contributor.author","Nagel, Holger"],["dc.date.accessioned","2018-11-07T11:00:53Z"],["dc.date.available","2018-11-07T11:00:53Z"],["dc.date.issued","2007"],["dc.description.abstract","We describe two newly established malignant mesothelioma (MM) cell lines derived from a pleural effusion of a male. One cell line, designated as MM-Z03E, reveals an epithelioid cobblestone morphology, while the second one, designated as MM-Z03S and subcloned after in vivo selection, exhibits a sarcomatoid storiform growth pattern. Both cell lines showed the immunologic profile characteristic for MM (i.e., expression of cytokeratin, CK18, calretinin, and vimentin in both phenotypes). Cytogenetics, multicolor fluorescence in situ hybridization, comparative genomic hybridization, and oligonucleotide array CGH were performed on both cell lines. Aberrations shared by both cell lines included chromosomal losses of 1q34 similar to qter, 4, 9p, 10p, 13, 14, 16q, 18, and 22, as well as a complex structural aberration involving chromosome 17. Aberrations exclusive to MM-Z03E included gains of 3q11q27 and 5p, while gain of 9q and losses of 3q27qter, 11q, and 18 in MM-Z03S were exclusive to MM-Z03E. Both cell lines were able to develop solid transplant tumors in nude mice within 16 weeks, and immunophenotyping of tumor xenografts revealed an overall retained expression profile of the markers used. Remarkably, one xenograft from MM-Z03E revealed overexpression of p53 and widely invasive growth. In conclusion, both cell lines are useful in vivo and in vitro model systems to study the underlying genetic mechanisms of biphasic differentiation in MM, which can be of certain value considering the increasing relevance of assessing MM tumor biology for the clinical management of this disease. (c) 2007 Elsevier Inc. All rights reserved."],["dc.identifier.doi","10.1016/j.cancergencyto.2007.03.005"],["dc.identifier.isi","000247710100004"],["dc.identifier.pmid","17574962"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/51027"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Inc"],["dc.relation.issn","0165-4608"],["dc.title","Establishment and characterization of two distinct malignant mesothelioma cell lines with common clonal origin"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","351"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Diagnostic Cytopathology"],["dc.bibliographiccitation.lastpage","358"],["dc.bibliographiccitation.volume","22"],["dc.contributor.author","Papaparaskeva, K."],["dc.contributor.author","Nagel, H."],["dc.contributor.author","Droese, M."],["dc.date.accessioned","2018-11-07T10:46:54Z"],["dc.date.available","2018-11-07T10:46:54Z"],["dc.date.issued","2000"],["dc.description.abstract","The cytomorphologic features in fine-needle aspiration (FNA) biopsies from 91 histologically verified medullary carcinomas of the thyroid (MCT) were investigated. FNA was able to diagnose neoplasms with indications of surgical removal in 98.9% of cases and moreover, was accurate in specific tumor typing in 89% of cases. The most important cytologic criteria of MCT with FNA are: dispersed cell-pattern of polygonal or triangular cells, azurophilic cytoplasmic granules, and extremely eccentrically placed nuclei with coarse granular chromatin and amyloid. These and other cytologic features of MCT are discussed in detail. Fourteen cases of thyroid tumors originally diagnosed as MCT by cytology are illustrated to discuss the differential diagnosis of MCT and its potential pitfalls. If MCT is cytologically presumed but amyloid and azurophilic cytoplasmic granules are not demonstrated, the use of immunostaining is necessary for a correct tumor typing. The application of immunocytochemistry in MCT is discussed. Diagn. Cytopathol. 2000;22:351-358. (C) 2000 Wiley-Liss, Inc."],["dc.identifier.isi","000087331700005"],["dc.identifier.pmid","10820528"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/47847"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-liss"],["dc.relation.issn","8755-1039"],["dc.title","Cytologic diagnosis of medullary carcinoma of the thyroid gland"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","60"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Diagnostic Molecular Pathology"],["dc.bibliographiccitation.lastpage","65"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Nagel, H."],["dc.contributor.author","Schlott, T."],["dc.contributor.author","Schulz, G. M."],["dc.contributor.author","Droese, M."],["dc.date.accessioned","2018-11-07T09:18:58Z"],["dc.date.available","2018-11-07T09:18:58Z"],["dc.date.issued","2001"],["dc.description.abstract","Diagnostic accuracy in effusion cytology based on morphologic examination is not always satisfactory. Therefore, various diagnostic adjuncts such as immunocytochemistry or deoxyribonucleic acid cytometry are employed in this diagnostic field. Recently, demonstration of telomerase activity has been proposed as a possible marker for malignancy. In this study a seminested reverse transcription-polymerase chain reaction (RT-PCR) strategy for expression analysis of the catalytic subunit of human telomerase (hEST2) was used in 58 serous effusions. RT-PCR results correlated with cytologic diagnoses in 14 of 17 malignant effusions. In eight effusions cytologically suspicious for malignancy, PCR results were in accordance with the clinical follow-up. However, hEST2 RT-PCR was also positive in six of 15 cytologically benign effusions that consisted predominantly of inflammatory and mesothelial cells. Using the telomeric repeat amplification protocol, it could be demonstrated that cultured, proliferating benign mesothelial cells may present a weak telomerase activity, as is known in other benign cells including activated lymphocytes. In conclusion, the simple and rapid method of hEST2 RT-PCR serves to support the cytologic diagnosis of malignancy, but false-positive PCR results resulting from activated lymphocytes and proliferating mesothelial cells must be considered."],["dc.identifier.doi","10.1097/00019606-200103000-00010"],["dc.identifier.isi","000167166200010"],["dc.identifier.pmid","11277397"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/28526"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.publisher.place","Philadelphia"],["dc.relation.eventlocation","JENA, GERMANY"],["dc.relation.issn","1052-9551"],["dc.title","Gene expression analysis of the catalytic subunit of human telomerase (hEST2) in the differential diagnosis of serous effusions"],["dc.type","conference_paper"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","4121"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Anticancer Research"],["dc.bibliographiccitation.lastpage","4125"],["dc.bibliographiccitation.volume","24"],["dc.contributor.author","Strik, Herwig M."],["dc.contributor.author","Spreer, Annette"],["dc.contributor.author","Nagel, Holger"],["dc.contributor.author","Jacob, Sonja"],["dc.contributor.author","Jung, Wolfram"],["dc.contributor.author","Kitze, Bernd"],["dc.contributor.author","Bähr, Mathias"],["dc.date.accessioned","2017-09-07T11:43:10Z"],["dc.date.available","2017-09-07T11:43:10Z"],["dc.date.issued","2004"],["dc.description.abstract","A 69-year-old female patient was treated for primary CNS-lymphoma (PCNSL) starting from August 2002. As her general condition allowed no high-dose methotrexate (MTX) therapy, radiotherapy was administered as a first-line treatment. CSF involvement could be managed by intrathecal Ara-C. Her general condition and cognitive status stabilized., but did not improve for 3 months. Therefore, oral chemotherapy with Temozolomide 200mg/m(2) was initiated. After two courses, which were tolerated without any problems, the patient's Karnofsky performance index had improved from 40% to 50%, the Mini-Mental Status rose from 16 to 27130. The CSF-cell count was elevated again to 23 cells/mul without signs of meningeal relapse. Unfortunately, the patient died unexpectedly front suspected pulmonary embolism. We conclude that adjuvant Temozolomide chemotherapy can improve the general condition and cognition in patients with PCNSL even when the general condition is poor. Long-term effects and neurotoxicity remain to be analysed in prospective trials, as well as the efficacy in leptomeningeal disease."],["dc.identifier.gro","3143931"],["dc.identifier.isi","000227014500066"],["dc.identifier.pmid","15736462"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/1499"],["dc.language.iso","en"],["dc.notes.intern","WoS Import 2017-03-10"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.relation.issn","0250-7005"],["dc.title","Clinical Response Following Adjuvant Temozolomide in a Patient with Primary Cerebral Lymphoma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","67"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Pathobiology"],["dc.bibliographiccitation.lastpage","76"],["dc.bibliographiccitation.volume","69"],["dc.contributor.author","Schlott, T."],["dc.contributor.author","Nagel, H."],["dc.contributor.author","Laskawi, Rainer"],["dc.contributor.author","Eiffert, Helmut"],["dc.contributor.author","Droese, M."],["dc.date.accessioned","2018-11-07T09:37:17Z"],["dc.date.available","2018-11-07T09:37:17Z"],["dc.date.issued","2001"],["dc.description.abstract","Introduction: Genetic alterations of oncogene MDM2 promote malignant transformation of several human tumors. In tumors of the salivary gland, however, the genetic status of MDM2 has not been evaluated so far. Methods and Results: Benign and malignant tumors of the salivary gland (6 pleomorphic adenomas, 3 Warthin's tumors, 1 adenocarcinoma, 1 basal cell adenocarcinoma, 1 mucoepidermoid carcinoma, 3 acinic cell carcinomas, 2 adenoid cystic carcinoma, 1 squamous cell carcinoma) were analyzed by fluorescence-based PCR techniques and immunochemistry for MDM2 gene amplification, MDM2 gene expression, MDM2 gene mutation, MDM2 RNA splicing and MDM2 accumulation. Data show that all samples contained nonamplified MDM2 genes with nonmutant zinc finger regions. However, in two benign and two malignant samples, novel MDM2 mRNA splicing variant types 1 and 2 were detected. Furthermore, three malignant tumors revealed significant nuclear MDM2 accumulation. Correlation between levels of MDM2 mRNA and MDM2 protein could not be detected in the specimens. Conclusion: The present study suggests that MDM2 gene mutation and gene amplification do not contribute to MDM2 accumulation detected in malignant tumors of the salivary gland. However, the role of novel MDM2 splicing variants in MDM2 expression and malignant transformation must be elucidated further. Copyright (C) 2001 S. Karger AG, Basel."],["dc.identifier.doi","10.1159/000048759"],["dc.identifier.isi","000173140900002"],["dc.identifier.pmid","11752900"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/32807"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.relation.issn","1015-2008"],["dc.title","Genetic analysis of the human oncoprotein MDM2 in benign and malignant tumors of the salivary gland"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","222"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Histopathology"],["dc.bibliographiccitation.lastpage","231"],["dc.bibliographiccitation.volume","44"],["dc.contributor.author","Nagel, H."],["dc.contributor.author","Laskawi, Rainer"],["dc.contributor.author","Wahlers, A."],["dc.contributor.author","Hemmerlein, Bernhard"],["dc.date.accessioned","2018-11-07T10:50:39Z"],["dc.date.available","2018-11-07T10:50:39Z"],["dc.date.issued","2004"],["dc.description.abstract","Aims: The balance between matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) is involved in the morphogenesis of the normal salivary gland as well as in mechanisms of tumour invasion and metastasis. Our aim was to analyse protein and mRNA expression of MMPs and TIMPs in normal salivary gland tissue and in various salivary gland neoplasms. Methods and results: Immunohistochemistry for MMP-2, MMP-9, TIMP-1, -2 and -3 was performed in 20 malignant and six benign salivary gland tumours. The immunoscores of MMP-2 were significantly higher in carcinomas compared with adenomas (P = 0.0028). The MMP/TIMP ratio was significantly higher in carcinomas than in adenomas (P = 0.0097). In mucoepidermoid carcinomas MMP-2 expression was preferentially observed in the intermediate cell type. Neoplastic acinar cells of acinic cell carcinoma demonstrated de novo expression of MMP-2, MMP-9, TIMP-1, and TIMP-2. Immunoscores of TIMP-3 were not decreased in malignant tumours compared with adenomas. In accordance with the immunostaining of MMP-2 and -9, gelatinolytic activity could be demonstrated by in-situ zymography. The mRNA expression of MMPs and TIMPs analysed by real-time reverse transcriptase-polymerase chain reaction in three malignant and two benign tumours and their corresponding normal tissue did not generally correlate with their protein expression. Conclusions: Our findings suggest a disturbed balance between MMP and TIMP in malignant salivary gland tumours. MMP-2 expression in particular seems to be related to the invasive properties and the malignant potential of these tumours."],["dc.identifier.doi","10.1111/j.0309-0167.2004.01814.x"],["dc.identifier.isi","000189293500004"],["dc.identifier.pmid","14987225"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/48705"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Blackwell Publishing Ltd"],["dc.relation.issn","0309-0167"],["dc.title","Expression of matrix metalloproteinases MMP-2, MMP-9 and their tissue inhibitors TIMP-1,-2, and-3 in benign and malignant tumours of the salivary gland"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Onkologie"],["dc.bibliographiccitation.volume","33"],["dc.contributor.author","Strik, Herwig Matthias"],["dc.contributor.author","Proemmel, Peter"],["dc.contributor.author","Buhk, J.-H."],["dc.contributor.author","Pilgram-Pastor, Sara M."],["dc.contributor.author","Nagel, I."],["dc.contributor.author","Perske, Christina"],["dc.contributor.author","Nagel, H."],["dc.date.accessioned","2018-11-07T08:46:29Z"],["dc.date.available","2018-11-07T08:46:29Z"],["dc.date.issued","2010"],["dc.format.extent","60"],["dc.identifier.isi","000274745200161"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/20701"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.publisher.place","Basel"],["dc.relation.issn","0378-584X"],["dc.title","Diagnosing Neoplastic Meningitis - the Value of MRI and Patterns of Lymphomatous Cytomorphology"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","818"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Modern Pathology"],["dc.bibliographiccitation.lastpage","825"],["dc.bibliographiccitation.volume","15"],["dc.contributor.author","Nagel, H."],["dc.contributor.author","Schulten, Hans-Juergen"],["dc.contributor.author","Gunawan, Bastian"],["dc.contributor.author","Brinck, Ulrich"],["dc.contributor.author","Fuzesi, Laszlo"],["dc.date.accessioned","2018-11-07T10:16:55Z"],["dc.date.available","2018-11-07T10:16:55Z"],["dc.date.issued","2002"],["dc.description.abstract","Comparative genomic hybridization (CGH) is a molecular cytogenetic technique that provides an overview on chromosomal imbalances within the whole tumor cell genome. This method has yet not been applied in effusion cytology. We performed CGH analysis in malignant effusions, fine needle aspirates, and imprint smears from eight ovarian adenocarcinomas, three breast carcinomas, one colon adenocarcinoma, and three malignant mesotheliomas. In part, CGH analysis from fresh frozen tissue and classic karyotyping served as controls. In this series, 14/15 cytologic specimens were suitable for extraction of high molecular weight DNA sufficient for reliable CGH analysis. CGH profiles from cytologic material were equal or even more significant in comparison with corresponding fresh frozen tumor samples. We conclude that CGH analysis from cytologic specimens may support the primary cytologic diagnosis of malignancy, especially in the differential diagnosis of benign proliferating mesothelium, malignant mesothelioma, and metastatic adenocarcinoma. CGH analysis of metastatic lesions may provide information on the site of the primary tumors and detects cytogenetic imbalances affecting oncogenes and tumor suppressor genes involved in tumor progression and metastatic spread."],["dc.identifier.doi","10.1097/01.MP.0000024521.67720.0F"],["dc.identifier.isi","000177543800005"],["dc.identifier.pmid","12181266"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/41130"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.relation.issn","0893-3952"],["dc.title","The potential value of comparative genomic hybridization analysis in effusion - and fine needle aspiration cytology"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","3"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","International Journal of Molecular Medicine"],["dc.bibliographiccitation.lastpage","8"],["dc.bibliographiccitation.volume","23"],["dc.contributor.author","Braunschweig, Till"],["dc.contributor.author","Krieg, R. C."],["dc.contributor.author","Bar-Or, R."],["dc.contributor.author","Smeets, D."],["dc.contributor.author","Schwamborn, K."],["dc.contributor.author","Fogt, F."],["dc.contributor.author","Nagel, H."],["dc.contributor.author","Hemmerlein, Bernhard"],["dc.contributor.author","Wellmann, A."],["dc.date.accessioned","2018-11-07T08:34:41Z"],["dc.date.available","2018-11-07T08:34:41Z"],["dc.date.issued","2009"],["dc.description.abstract","Ascites is a common clinical symptom in liver cirrhosis, inflammatory disorders of the abdomen and a major late manifestation of metastatic malignancies. Standard cytopathological techniques and immunocytochemistry have specificities and sensitivities of similar to 95 and 60%, respectively for the presence of tumor cells. Development of faster and more accurate screening methods would be of great clinical utility. In this work we examined differential analysis of the unbound proteins in the supernatant of ascites fluid by Protein-Chip SELDI mass spectrometry. There were 21 tumor cell-positive and 34 tumor cell-negative samples. We used principal component analysis coupled with linear regression applied to the mass spectra of the samples to distinguish between the sample groups. Two sample sets for statistical analysis were created after randomization, a training set with 37 samples and a validation set with 18 samples resulting in a specificity of 93% and a sensitivity of 83% on the training set. The validation set yielded a specificity and sensitivity of 75%. This study suggests that SELDI-TOF mass spectrometry appears to have great potential as a Surrogate diagnostic tool to evaluate effusion specimens."],["dc.description.sponsorship","Wilhelm Sander-Stiftung [2004.055.1]"],["dc.identifier.doi","10.3892/ijmm_00000095"],["dc.identifier.isi","000262014000001"],["dc.identifier.pmid","19082501"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/17876"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Professor D A Spandidos"],["dc.relation.issn","1107-3756"],["dc.title","Protein profiling of non-malignant and malignant ascites by SELDI-TOF MS: Proof of principle"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","226"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Molecular Pathology"],["dc.bibliographiccitation.lastpage","231"],["dc.bibliographiccitation.volume","56"],["dc.contributor.author","Nagel, H"],["dc.date.accessioned","2021-06-01T10:47:40Z"],["dc.date.available","2021-06-01T10:47:40Z"],["dc.date.issued","2003"],["dc.description.abstract","Aims: Molecular genetic changes involved in tumorigenesis and malignant transformation of human tumours are novel targets of cancer diagnosis and treatment. This study aimed to analyse the expression of putative tumour suppressor genes, FHIT and WT-1, and tumour rejection genes, BAGE, GAGE-1/2, MAGE-1, MAGE-3, and HAGE ( which are reported to be important in human cancers), in salivary gland neoplasms. Methods: Gene expression was analysed by reverse transcription polymerase chain reaction (RT-PCR) in normal salivary gland tissue and 44 benign and malignant salivary gland tumours. Results: Aberrant FHIT transcripts were found in one of 38 normal salivary glands, three of 28 adenomas, and two of 16 carcinomas. WT-1 mRNA was detectable in two adenomas and five carcinomas. Immunoblotting showed that WT-1 mRNA expression was associated with raised WT-1 protein concentrations. RT-PCR for detection of BAGE, GAGE, and MAGE gene expression was positive in two adenomas and nine carcinomas, but negative in normal salivary gland tissue. HAGE mRNA was found in two normal salivary glands, 11 benign, and eight malignant tumours. Conclusions: FHIT mRNA splicing does not appear to be involved in the genesis of salivary gland neoplasms. The upregulation of WT-1 mRNA in tumours of epithelial/myoepithelial phenotype may imply a potential role of WT-1 in the genesis and/or cellular differentiation of these salivary gland tumours. The tumour rejection genes were more frequently, but not exclusively, expressed in malignant salivary gland tumours than in benign neoplasms, although none was suitable as a diagnostic marker of malignancy in salivary gland neoplasms."],["dc.identifier.doi","10.1136/mp.56.4.226"],["dc.identifier.isi","000184713100006"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/85679"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","British Med Journal Publ Group"],["dc.relation.issn","1366-8714"],["dc.title","Analysis of the tumour suppressor genes, FHIT and WT-1, and the tumour rejection genes, BAGE, GAGE-1/2, HAGE, MAGE-1, and MAGE-3, in benign and malignant neoplasms of the salivary glands"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]